Oxford University Innovation Ltd. welcomes the announcement by Eykona, an Oxford-based medical technology company, that it has completed an investment round of £1.19m. The round, which was over-subscribed, allows Eykona to progress its innovative 3D wound imaging system to launch and beyond.
A £1.55m fundraising round has been successfully completed by Crysalin Limited, a company founded as a spinout from the University of Oxford Biochemistry Department by Oxford University Innovation Limited.
OrganOx Ltd, spun-out of the University of Oxford by Oxford University Innovation Ltd in 2008, has completed a Series B investment round of £2.75m. The round, which was over-subscribed, was supported by existing shareholders and a number of new ones, including the Royal Society.
TissueFlex® addresses the missing link between conventional 2D assays and in vivo studies, providing a true three-dimensional (3D) platform for in vitro cultures with more in vivo-like behaviour to improve the predictivity of drug safety and efficacy testing.
A fund designed to bridge the "innovation gap", supporting University of Oxford inventors in proof of concept and prototyping work, has reached its first close and made its first investment in a new class of antibiotics discovered in a natural product library at the University of Oxford's Department of Chemistry.
Isis continues to deliver a positive return on investment to the University each year; receiving £2.5m pa from the University and this year returning £4.8m (up from £4.5m in 2010) to the University and its researchers from royalties, consulting and profit, by means of gift aid payments. In addition to this Isis delivers a wide range of further benefits to the University in both financial and non-financial terms. We are grateful to the University for its continued support.
Oxtex Limited, the newest spin-out from Oxford University Innovation Ltd, the technology transfer office of the University of Oxford, has secured £365,000 of seed funding to develop an intelligent hydrogel material for tissue expansion. For the first time, surgeons will be able to accurately and predictably control the direction, the timing, and rate of the material’s expansion in the body. This will significantly reduce the risk of soft tissue damage and associated complications. The level of control makes them ideal for use in delicate anatomical locations, particularly in the treatment of children.
Treating only patients who are likely to benefit from anti-cancer drugs and identifying quickly which treatment is best for each person, is the aim behind a new spin-out from the University of Oxford, Oxford Cancer Biomarkers Limited (OCB).
Oxford-developed software which builds on a deep understanding of linguistics to assess accurately what people mean from what they say online will provide a “sentiment analysis” tool for businesses, particularly finance companies. The new company, TheySay, has been set up by the University’s technology transfer company, Oxford University Innovation and today announced it had received first-round investment of up to £500,000 from IP Group plc.
The Oxford Thinking Campaign has now passed its initial target of £1.25 billion raised for the collegiate University.
